【创新药概念震荡反弹 昂利康涨停】智通财经10月15日电，创新药概念盘中震荡反弹，昂利康涨停， 广生堂涨超10%，热景生物、联环药业、舒泰神、荣昌生物等涨幅靠前。消息面上，2025年欧洲肿瘤内 科学会（ESMO）年会定于10月17日至10月21日在德国柏林举行，作为全球肿瘤学领域的顶级盛会，此 次会议预计将汇集多项重磅临床研究成果。 转自：智通财经 ...

Core Viewpoint - Zhejiang Anglikang Pharmaceutical Co., Ltd. has received the drug registration certificate for Measartan Potassium Tablets from the National Medical Products Administration, which is expected to enhance the company's product pipeline and market presence [1] Group 1: Product Approval - The drug Measartan Potassium Tablets has been approved in two specifications: 40mg and 80mg [1] - The approval number is valid until September 29, 2030, indicating a long-term market presence [1] - The drug is indicated for the treatment of adult primary hypertension, addressing a significant health issue [1] Group 2: Market Impact - The approval is considered equivalent to passing the consistency evaluation, which may positively influence the company's market competitiveness [1] - The company received the acceptance notice for this drug in 2024, suggesting a proactive approach to expanding its product offerings [1] Group 3: Industry Considerations - The pharmaceutical industry is subject to various factors such as policies and market dynamics, which can impact drug sales and overall performance [1] - The company has advised investors to remain cautious regarding potential risks associated with the pharmaceutical market [1]

证券代码：002940 证券简称：昂利康 公告编号：2025-072 浙江昂利康制药股份有限公司 1 家相关政策规定，本次获得《药品注册证书》视同通过一致性评价。 三、对公司的影响 本次美阿沙坦钾片获得药品注册证书，将进一步丰富公司产品管线。由于医 药行业的特殊性，药品的销售容易受到国家政策、市场环境变化等因素影响，具 体销售情况存在较大不确定性。 敬请广大投资者审慎决策，注意投资风险。 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）签发的美阿沙坦钾片《药品注册证书》， 现将有关情况公告如下： | 药品通用名称 | 美阿沙坦钾片 | | | --- | --- | --- | | 主要成份 | 美阿沙坦钾 | | | 剂型 | 片剂 | | | 申请事项 | 药品注册（境内生产） | | | 注册分类 | 化学药品 4 类 | | | 规格 | 按美阿沙坦（C₃₀H₂₄N₄O₈）计 按美阿沙坦（C₃₀H₂₄N₄O₈）计 | | | ...

Core Viewpoint - The company, Anglikang, has announced a share buyback plan, indicating confidence in its business and future growth potential, while also focusing on enhancing employee incentives through stock ownership [1][2] Group 1: Share Buyback and Financials - Anglikang has repurchased a total of 3,599,700 shares, accounting for approximately 1.78% of its total share capital, with a total transaction amount of 50,001,275.28 yuan [1] - The buyback price range was between 12.17 yuan and 17.00 yuan per share, with a planned total expenditure of no less than 50 million yuan and no more than 70 million yuan [1] - The company aims to use the repurchased shares for future employee stock ownership plans or equity incentives [1] Group 2: Business Operations and Market Position - Anglikang primarily engages in the production and manufacturing of pharmaceuticals, including chemical raw materials, formulations, and specialized intermediates [1] - The company has established a comprehensive industrial chain in the production of oral cephalosporins and other pharmaceutical products, enhancing its market competitiveness [1] - The customer structure is clear, with domestic sales accounting for 75.85% and international sales for 24.15%, focusing on large pharmaceutical and chemical companies [2] Group 3: Research and Development - In the first half of 2025, the company's R&D investment reached 85.6 million yuan, representing 11.82% of its operating revenue, resulting in the acquisition of 4 invention patents and 5 utility model patents [3] - The product line includes core products with high market share and new formulations that have won centralized procurement bids, aiding market expansion [3] - The company is developing innovative drugs, with several candidates entering clinical trials, establishing a complete product pipeline from generics to innovative drugs [3] Group 4: Strategic Growth and Future Prospects - The acquisition of Keri Bio has strengthened Anglikang's cash flow and market position, with Keri Bio expected to achieve a net profit margin of 40% in 2024 [4] - The company is focusing on the pet medicine sector, with ambitious sales targets and numerous projects in the pipeline, which are anticipated to become new growth drivers [4] - Anglikang has implemented environmentally friendly production techniques and established a comprehensive quality management system, aligning with industry standards [3]

Core Insights - The Chinese innovative pharmaceutical industry is experiencing a "double hit" in performance and valuation due to policy support, R&D breakthroughs, and value reassessment [1] - Many innovative drug stocks have doubled in price this year, with pharmaceutical-themed funds averaging a nearly 40% increase in net value over the past year [1] - The industry is entering a long-term growth trajectory, with current valuations still considered attractive by both domestic and foreign institutions [1] Group 1: Stock Performance - Several innovative drug companies have seen significant stock price increases, with companies like Shuyou Shen, Rongchang Bio, and Anglikang all experiencing over 100% growth year-to-date as of October 9 [1] - Pharmaceutical-themed funds have also shown strong performance, with the average net value increasing nearly 40% over the past year, and some funds, such as Penghua Innovation Upgrade Mixed A, seeing gains exceeding 100% [1] Group 2: Institutional Interest - There has been a surge in institutional research on Chinese innovative drug companies, with companies like Baiji Shenzhou and Baili Tianheng receiving attention from 213 and 186 institutions respectively [2] - Notable foreign institutions, including State Street Bank and BlackRock, have participated in the research of these companies, indicating growing international interest [2] Group 3: Industry Trends - The innovative drug sector is transitioning from "burning cash on R&D" to "product volume expansion," marking the beginning of a profit harvest period [3] - Chinese innovative drug companies have significantly improved their R&D capabilities and gained international recognition, positioning themselves in the global first tier in terms of pipeline quantity [3] - The industry is expected to achieve a systematic value reassessment, driven by comprehensive policy support and high levels of R&D and clinical efficiency [2][3]

格隆汇10月9日丨昂利康(002940.SZ)公布，截至2025年9月30日，公司通过回购专用证券账户以集中竞 价交易方式累计回购股份数量为3,599,700股，约占公司总股本的1.78%，最高成交价为17.00元/股，最 低成交价为12.17元/股，交易总金额50,001,275.28元（不含交易费用）。本次回购符合公司回购方案的 要求。 ...

截至发稿，昂利康市值为75亿元。 每经头条（nbdtoutiao）——与美元脱钩后，暴涨102倍，揭秘黄金疯涨背后神秘的"无形之手"！专家： 推动金价上涨的逻辑没有变 （记者 张明双） 每经AI快讯，昂利康（SZ 002940，收盘价：37.4元）10月9日晚间发布公告称，截至2025年9月30日， 公司通过回购专用证券账户以集中竞价交易方式累计回购股份数量约为360万股，约占公司总股本的 1.78%，最高成交价为17元/股，最低成交价为12.17元/股，交易总金额约5000万元。 2025年1至6月份，昂利康的营业收入构成为：医药制造业占比100.0%。 ...

证券代码：002940 证券简称：昂利康 公告编号：2025-071 （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； 浙江昂利康制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日召 开第四届董事会第六次会议，审议通过了《关于回购公司股份方案的议案》，同 意公司使用自有资金及股票回购专项贷款以集中竞价的方式回购公司部分已发 行的社会公众股份，回购的股份将用于后续员工持股计划或者股权激励。本次回 购股份的资金总额不低于人民币5,000万元（含）且不超过人民币7,000万元（含）， 回购价格不超过人民币 21.07 元/股（含）。具体回购股份的数量以公司实际回购 的股份数量为准。本次回购股份的实施期限为自董事会审议通过本次回购股份方 案之日起不超过 12 个月。具体内容详见公司于 2024 年 11 月 5 日、2024 年 11 月 8 日在指定信息披露媒体《证券时报》及巨潮资 ...

Core Viewpoint - The stock of Anglikang has shown significant volatility, with a year-to-date increase of 192.23%, but recent declines in the short term raise questions about future performance [1][2]. Company Overview - Anglikang Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company focuses on the research, production, and sales of chemical raw materials and formulations [1]. - The main revenue composition includes formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1]. Financial Performance - For the first half of 2025, Anglikang reported operating revenue of 724 million yuan, a year-on-year decrease of 14.52%, and a net profit attributable to shareholders of 65.93 million yuan, down 3.19% year-on-year [2]. - Since its A-share listing, Anglikang has distributed a total of 341 million yuan in dividends, with 108 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 50.49% to 18,500, with an average of 10,037 circulating shares per person, a decrease of 33.55% [2]. - Notable new institutional shareholders include China Europe Medical Health Mixed A, holding 6.44 million shares, and Guangfa Technology Innovation Mixed A, holding 6.16 million shares [3].

证券日报网讯 9月24日晚间，昂利康发布公告称，公司于2025年9月23日召开第四届董事会第十一次会 议，审议通过了《关于第一期员工持股计划存续期展期的议案》，同意将公司第一期员工持股计划的存 续期展期12个月，即存续期展期至2026年11月2日。 （编辑 楚丽君） ...